Kato van Vooren SRL
Kato van Vooren reported total assets of 88,886 € at the end of the 2025 financial year (annual accounts filed with the NBB on 28 Aug 2026).
The score of Kato van Vooren shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +74 % Total assets +66 %
Accounts of the company itself (not consolidated).
The full file covers 7 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Kato van Vooren's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 28 Aug 2026
- Year ended 31 Dec 2024filed on 17 Oct 2025
- Year ended 31 Dec 2023filed on 30 Aug 2024
- Year ended 31 Dec 2022filed on 31 Aug 2023
- Year ended 31 Dec 2021filed on 08 Sep 2022
Kato van Vooren's financial analysis
- Solvency81.2%sector median: 44.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Kato van Vooren
Kato van Vooren's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0702.941.875
- VAT number
- BE0702941875
- Peppol
- Registered · 0208:0702941875 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 07 Sep 2018
- Registered office
- 9200 Dendermonde
- Latest accounts
- 2025 · filed on 28 Aug 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Kato van Vooren (SRL) has been based in Dendermonde since 2018, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 14,306 € and equity of 72,194 €; its revenue is not published. Its solvency stands at 81.2%, above the median of its sector (44.2%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Kato van Vooren
Companies in the same business, of comparable size and area, outside its group.
- Yascare Retail sale of pharmaceutical products Uccle · balance sheet 34,424 €
- Van Aelst Leonie Retail sale of pharmaceutical products Beernem · balance sheet 86,688 €
- NT Farma Retail sale of pharmaceutical products Mouscron · balance sheet 56,255 €
- Panax Retail sale of pharmaceutical products Wemmel · balance sheet 99,320 €
- Curasan Retail sale of pharmaceutical products Zwalm · balance sheet 103,974 €
- Tilosa Retail sale of pharmaceutical products Lokeren · balance sheet 70,195 €
- MGS Pharma Retail sale of pharmaceutical products Stavelot · balance sheet 68,803 €
- Apocurae Retail sale of pharmaceutical products Kortemark · balance sheet 124,948 €
Frequently asked questions about Kato van Vooren
What is the revenue of Kato van Vooren?
Kato van Vooren files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Kato van Vooren?
In Belgium, the VAT number is the company number prefixed with BE: BE0702941875 for Kato van Vooren, if the company is VAT-registered. Its company number (CBE) is 0702.941.875.
Where is the registered office of Kato van Vooren?
According to the CBE register, the registered office of Kato van Vooren is in 9200 Dendermonde.
What is the equity of Kato van Vooren?
At the close of the 2025 financial year, the equity of Kato van Vooren amounts to 72,194 €, a solvency of 81.2% of total assets.
Who manages Kato van Vooren?
The register lists 1 active mandates at Kato van Vooren. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Kato van Vooren
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →